RxDoctor Payments Data

Henry Gor, MD

Obstetrics & Gynecology · Longview, TXNPI 1386612307

Payments from drug & device makers

$6,721in general payments, 2019–2025

Across 251 payments — averaging $26.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Fujirebio Diagnostics, Incorporated$725
  • Mayne Pharma Commercial LLC$699
  • Astellas Pharma US Inc$426
  • Amgen$406
  • Exeltis, USA Inc.$386
  • plus $3K from 32 others

What the payments were for

  • Consulting fees$3665%
  • Food & beverage$6,11991%
  • Education$2364%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,721 in reported general payments places this provider in the 85th percentile of 3,099 obstetrics & gynecology providers in Texas.

See all obstetrics & gynecology providers in Texas

Medicare billing

Part B allowed, 2024
$11,497
Medicare patients
58
Services billed
203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron14$6,632
IntrarosaPrasterone (Dhea)12$3,983
Raloxifene Hcl57$2,021
Estradiol45$1,871
Solifenacin Succinate28$692
ProgesteroneProgesterone, Micronized17$365
Paroxetine Hcl12$333
Venlafaxine Hcl ErVenlafaxine Hcl15$323
Escitalopram Oxalate19$280
Alendronate Sodium26$83
Buspirone Hcl11$45

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$426$6,63214 claims
AMAG Pharmaceuticals, Inc.Intrarosa$16$3,98312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,099 obstetrics & gynecology providers in Texas.

Other obstetrics & gynecology in Longview

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →